Top

Published in:

29-01-2024 | Cystic Fibrosis | Review

Fungal Respiratory Colonization and Infections in Cystic Fibrosis Patients in the Middle East

Authors: Mohammad T. Hedayati, Mona Ghazanfari, Bahador Nikoueian Shirvan, Sabrieh Asadi Shahi Sarae, Somayeh Ghanbari, Sanaz Yaalimadad, Shima Parsay, Shakiba Hedayati, Neda Hedayati, Martin Hoenigl

Published in: Current Fungal Infection Reports | Issue 1/2024

Abstract

Purpose of Review

Cystic fibrosis (CF) is an inherited disease that can progressively affect multiple organs including respiratory tract. CF has been believed to occur infrequently in the Middle East (ME). However, it seems that CF maybe more common in ME countries than expected before. Despite the fact that surveillance of fungal infections is essential, data in the ME region remain scarce. This narrative review aims to evaluate the previously published data on the prevalence of fungal respiratory colonization and infections, spectrum of isolated fungi from the respiratory tract, and antifungal treatment in CF patients across ME countries.

Recent Findings

Among different opportunistic fungal pathogens, Aspergillus fumigatus and Candida species were reported as the most prevalent mold and yeast like fungi isolated from respiratory tract of CF patients from ME countries. A. fumigatus was reported as the common filamentous colonizing fungi of the respiratory tract of CF patients from Turkey in the range 10.4–76.3%. Colonization due to Aspergillus also showed the highest frequency for A. fumigatus (50.0%) in CF patients from Qatar. However, in a more comprehensive study from Iran, A. flavus was the most common. Scedosporium spp. has not been reported in CF patients from ME countries except for one study in Iran.

Summary

Future efforts should focus on improving laboratory capacities in ME for detection of common and rare fungal pathogens. National CF registries could help to collect more systematic data on fungal colonization and infection in patients in the ME.

Mirtajani SB, Farnia P, Hassanzad M, Ghanavi J, Farnia P, Velayati AA. Geographical distribution of cystic fibrosis; the past 70 years of data analyzis. Biomed Biotechnol Res J. 2017;1(2):105–12. https://doi.org/10.4103/bbrj.bbrj_81_17.CrossRef

Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2020;10:1662. https://doi.org/10.3389/fphar.2019.01662.CrossRefPubMedPubMedCentral

Chillón M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332(22):1475–80. https://doi.org/10.1056/NEJM199506013322204.CrossRefPubMed

Page A, Goldenberg A, Matthews AL. Lived experiences of individuals with cystic fibrosis on CFTR-modulators. BMC Pulm Med. 2022;22(1):1–12. https://doi.org/10.1186/s12890-022-01825-2.CrossRef

De Boeck K, Zolin A, Cuppens H, Olesen H, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros. 2014;13(4):403–9. https://doi.org/10.1016/j.jcf.2013.12.003.CrossRefPubMed

Bonyadi M, Omrani O, Rafeey M, Bilan N. Spectrum of CFTR gene mutations in Iranian Azeri Turkish patients with cystic fibrosis. Genet Test Mol Biomarkers. 2011;15(1–2):89–92. https://doi.org/10.1089/gtmb.2010.0091.CrossRefPubMed

Zamani RAM. Mutation analysis of CFTR gene in 70 Iranian cystic fibrosis patients. Iran J Allergy Asthma Immunol. 2006:3–8

Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575–606. https://doi.org/10.1002/humu.10041.CrossRefPubMed

Oskooei VK, Dooki MRE, Tabaripour R, Mirzajani S, Pourbagher R, Akhavan-Niaki H. CFTR haplotypes in northern Iranian population. Gene. 2013;512(1):55–60. https://doi.org/10.1016/j.gene.2012.09.096.CrossRef

10.

Hosseini Nami A, Kabiri M, Zafarghandi Motlagh F, Shirzadeh T, Fakhari N, Karimi A, et al. Genetic attributes of Iranian cystic fibrosis patients: the diagnostic efficiency of CFTR mutations in over a decade. Front Genet. 2023;14:1140034. https://doi.org/10.3389/fgene.2023.1140034.CrossRefPubMedPubMedCentral

11.

Thomas M, Aboukhalaf S, Darwish T, Ali M, Elsaied O, Al Bakri M, et al. The spectrum of fungal colonization and their attributable effects on cystic fibrosis patients with rare CFTR genetic mutations. Microbiol Res. 2021;12(3):591–605. https://doi.org/10.3390/microbiolres12030042.CrossRef

12.

Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450–3. https://doi.org/10.1016/j.jcf.2008.03.007.CrossRefPubMed

13.

Silva Filho LVRF, Castaños C, Ruíz HH. Cystic fibrosis in Latin America—improving the awareness. J Cyst Fibros. 2016;15(6):791–3. https://doi.org/10.1016/j.jcf.2016.05.007.CrossRefPubMed

14.

Scotet V, Gutierrez H, Farrell PM. Newborn screening for CF across the globe—where is it worthwhile? Int J Neonatal Screen. 2020;6(1):18. https://doi.org/10.3390/ijns6010018.CrossRefPubMedPubMedCentral

15.

Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195–211. https://doi.org/10.1016/s0140-6736(20)32542-3.CrossRefPubMed

16.

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65–124. https://doi.org/10.1016/s2213-2600(19)30337-6.CrossRefPubMed

17.

Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456–62. https://doi.org/10.1016/j.jcf.2022.01.009.CrossRefPubMed

18.

da Silva LVRF, Zampoli M, Cohen-Cymberknoh M, Kabra SK. Cystic fibrosis in low and middle-income countries (LMIC): a view from four different regions of the world. Paediatr Respir Rev. 2021;38:37–44. https://doi.org/10.1016/j.prrv.2020.07.004.CrossRef

19.

Aghamohammadi A, Keivanfar M, Navaei S, Shirzadi R, Masiha F, Allameh Z, et al. First cystic fibrosis patient registry annual data report-cystic fibrosis foundation of Iran. Acta Med Iran. 2019:33–41.https://doi.org/10.18502/acta.v57i1.1751.

20.

Dogru D, Çakır E, Şişmanlar T, Çobanoğlu N, Pekcan S, Cinel G, et al. Cystic fibrosis in Turkey: First data from the national registry. Pediatr Pulmonol. 2020;55(2):541–8. https://doi.org/10.1002/ppul.24561.CrossRefPubMed

21.

Stafler P, Mei-Zahav M, Wilschanski M, Mussaffi H, Efrati O, Lavie M, et al. The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening. J Cyst Fibros. 2016;15(4):460–6. https://doi.org/10.1016/j.jcf.2015.08.007.CrossRefPubMed

22.

Cuppens H, Boulyjenkov V, Cassiman J, Cutting G, Dodge J, Des Georges M, et al. The molecular genetic epidemiology of cystic fibrosis: report of a joint meeting of WHO/ECFTN/ICF (M) A/ECFS. 2004

23.

Desgeorges M, Mégarbané A, Guittard C, Carles S, Loiselet J, Demaille J, Claustres M. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. Hum Genet. 1997;100:279–83. https://doi.org/10.1007/s004390050505.CrossRefPubMed

24.

Al-Mahroos F. Cystic fibrosis in Bahrain incidence, phenotype, and outcome. J Trop Pediatr. 1998;44(1):35–9. https://doi.org/10.1093/tropej/44.1.35.CrossRefPubMed

25.

Havasian MR, Panahi J, Mahdieh N. Cystic fibrosis and distribution and mutation analysis of CFTR gene in Iranian patients. Faslnamahi Kumish. 2014;15(4):431–40.

26.

https://worldpopulationreview.com/country-rankings/middle-east-countries. Accessed November 1, 2023.

27.

Quittner AL, Schechter MS, Rasouliyan L, Haselkorn T, Pasta DJ, Wagener JS. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest. 2010;137(3):642–50.CrossRefPubMed

28.

Palla JB. Disparities and therapeutic advances in cystic fibrosis. Pediatr Pulmonol. 2023. https://doi.org/10.1002/ppul.26445.CrossRefPubMed

29.

Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community—implications for therapeutic management. PLoS ONE. 2012;7(4):e36313. https://doi.org/10.1371/journal.pone.0036313.ADSCrossRefPubMedPubMedCentral

30.

Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91–100. https://doi.org/10.1002/ppul.10127.CrossRefPubMed

31.

Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2009;154(2):183–8. https://doi.org/10.1016/j.jpeds.2008.08.001.CrossRefPubMed

32.

Salsgiver EL, Fink AK, Knapp EA, LiPuma JJ, Olivier KN, Marshall BC, Saiman L. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest. 2016;149(2):390–400. https://doi.org/10.1378/chest.15-0676.CrossRefPubMedPubMedCentral

33.

Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol. 2018;53(S3):S75–85. https://doi.org/10.1002/ppul.24126.CrossRefPubMed

34.

Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros. 2010;9(2):110–6. https://doi.org/10.1016/j.jcf.2009.11.010.CrossRefPubMed

35.

Yan K, Yin H, Wang J, Cai Y. Subtle relationships between Pseudomonas aeruginosa and fungi in patients with cystic fibrosis. Acta Clin Belg. 2022;77(2):425–35. https://doi.org/10.1080/17843286.2020.1852850.CrossRefPubMed

36.

Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens? J Biochem Cell Biol. 2014;52:161–73. https://doi.org/10.1016/j.biocel.2014.03.001.CrossRef

37.

Touati K, Nguyen DNL, Delhaes L. The airway colonization by opportunistic filamentous fungi in patients with cystic fibrosis: recent updates. Curr Fungal Infect Rep. 2014;8:302–11. https://doi.org/10.1007/s12281-014-0197-7.CrossRef

38.

Gileles-Hillel A, Shoseyov D, Polacheck I, Korem M, Kerem E, Cohen-Cymberknoh M. Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis. Pediatr Pulmonol. 2015;50(11):1082–9. https://doi.org/10.1002/ppul.23302.CrossRefPubMed

39.

De Jong C, Slabbers L, Engel T, Yntema J, van Westreenen M, Croughs P, et al. Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: A nationwide study. Med Mycol. 2020;58(7):859–66. https://doi.org/10.1093/mmy/myaa003.CrossRefPubMedPubMedCentral

40.

Abdolrasouli A, Bercusson AC, Rhodes JL, Hagen F, Buil JB, Tang AY, et al. Airway persistence by the emerging multi-azole-resistant Rasamsonia argillacea complex in cystic fibrosis. Mycoses. 2018;61(9):665–73. https://doi.org/10.1111/myc.12789.CrossRefPubMed

41.

Hoenigl M, Salmanton-García J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021. https://doi.org/10.1016/s1473-3099(20)30784-2.CrossRefPubMed

42.

Sedlacek L, Graf B, Schwarz C, Albert F, Peter S, Würstl B, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst Fibros. 2015;14(2):237–41. https://doi.org/10.1016/j.jcf.2014.12.014.CrossRefPubMed

43.

Seufert R, Sedlacek L, Kahl B, Hogardt M, Hamprecht A, Haase G, et al. Prevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany. J Antimicrob Chemother. 2018;73(8):2047–53. https://doi.org/10.1093/jac/dky147.CrossRefPubMed

44.

Stathi A, Loukou I, Kirikou H, Petrocheilou A, Moustaki M, Velegraki A, Zachariadou L. Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019. Euro Surveill. 2019;24(29):1900400. https://doi.org/10.2807/1560-7917.ES.2019.24.29.1900400.CrossRefPubMedPubMedCentral

45.

Jenks JD, Seidel D, Cornely OA, Chen S, van Hal S, Kauffman C, et al. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019. Clin Microbiol Infect. 2020:S1198–743X(20)30037–9.https://doi.org/10.1016/j.cmi.2020.01.012.

46.

Boyer J, Feys S, Zsifkovits I, Hoenigl M, Egger M. Treatment of invasive Aspergillosis: how it’s going, where it’s heading. Mycopathologia. 2023. https://doi.org/10.1007/s11046-023-00727-z.CrossRefPubMedPubMedCentral

47.

Janahi IA, Rehman A, Al-Naimi AR. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ann Thorac Med. 2017;12(2):74. https://doi.org/10.4103/atm.ATM_231_16.CrossRefPubMedPubMedCentral

48.

Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137(1):171–6. https://doi.org/10.1378/chest.09-1103.CrossRefPubMed

49.

Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol. 2013;132(3):560–6. https://doi.org/10.1016/j.jaci.2013.04.007.CrossRefPubMed

50.

King J, Brunel SF, Warris A. Aspergillus infections in cystic fibrosis. J Infect. 2016;72:S50–5.CrossRefPubMed

51.

Antunes J, Fernandes A, Borrego LM, Leiria-Pinto P, Cavaco J. Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol (Madr). 2010;38(5):278–84. https://doi.org/10.1016/j.aller.2010.06.002.CrossRefPubMed

52.

Henry M, Bennett D, Kiely J, Kelleher N, Bredin C. Fungal atopy in adult cystic fibrosis. Respir Med. 2000;94(11):1092–6. https://doi.org/10.1053/rmed.2000.0918.CrossRefPubMed

53.

Tobin M, Maguire O, Reen D, Tempany E, Fitzgerald M. Atopy and bronchial reactivity in older patients with cystic fibrosis. Thorax. 1980;35(11):807–13. https://doi.org/10.1136/thx.35.11.807.CrossRefPubMedPubMedCentral

54.

Poore TS, Meier M, Towler E, Martiniano SL, Brinton JT, DeBoer EM, et al. Clinical characteristics of people with cystic fibrosis and frequent fungal infection. Pediatr Pulmonol. 2022;57(1):152–61. https://doi.org/10.1002/ppul.25741.CrossRefPubMed

55.

Poore TS, Hong G, Zemanick ET. Fungal infection and inflammation in cystic fibrosis. Pathogens. 2021;10(5):618. https://doi.org/10.3390/pathogens10050618.CrossRefPubMedPubMedCentral

56.

Hassanzad M, Mortezaee V, Bongomin F, Poorabdollah M, Sharifynia S, Maleki M, et al. Successful control of exacerbation of allergic bronchopulmonary aspergillosis due to Aspergillus terreus in a cystic fibrosis patient with short-term adjunctive therapy with voriconazole: a case report. J Mycol Med. 2019;29(2):189–92. https://doi.org/10.1016/j.mycmed.2019.02.001.CrossRefPubMed

57.

Maleki M, Mortezaee V, Hassanzad M, Mahdaviani S, Poorabdollah M, Mehrian P, et al. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis patients using two different diagnostic criteria. Eur Ann Allergy Clin Immunol. 2020;52(3):104–11. https://doi.org/10.23822/eurannaci.1764-1489.121.CrossRefPubMed

58.

Alyasin S, Moghtaderi M, Farjadian S, Babaei M, Teshnizi SH. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. Electron Physician. 2018;10(1):6273. https://doi.org/10.19082/6273.CrossRefPubMedPubMedCentral

59.

Khalilzadeh S, Hassanzad M, Toutkaboni MP, Nejad ST, Sheikholeslami F-M, Velayati AA. Reappraisal of frequency of common cystic fibrosis transmembrane conductance regulator gene mutations in Iranian cystic fibrosis patients. Tanaffos. 2018;17(2):73.PubMedPubMedCentral

60.

Yakut N, Kadayifci EK, Eralp EE, Gokdemir Y. Successful treatment of allergic bronchopulmonary aspergillosis with posaconazole in a child with cystic fibrosis: case report and review of the literature. Lung India. 2020;37(2):161. https://doi.org/10.4103/lungindia.lungindia_288_19.CrossRefPubMedPubMedCentral

61.

Cakir E, Uyan Z, Ersu RH, Karadag B, Karakoc F, Dagli E. Mucoid impaction: an unusual form of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis. Pediatr Pulmonol. 2006;41(11):1103–7. https://doi.org/10.1002/ppul.20499.CrossRefPubMed

62.

Emiralioglu N, Dogru D, Tugcu GD, Yalcin E, Kiper N, Ozcelik U. Omalizumab treatment for allergic bronchopulmonary aspergillosis in cystic fibrosis. Ann Pharmacother. 2016;50(3):188–93. https://doi.org/10.1177/1060028015624204.CrossRefPubMed

63.

Nasri E, Fakhim H, Vaezi A, Khalilzadeh S, Ahangarkani F, Laal Kargar M, et al. Airway colonisation by Candida and Aspergillus species in Iranian cystic fibrosis patients. Mycoses. 2019;62(5):434–40. https://doi.org/10.1111/myc.12898.CrossRefPubMed

64.

Kartal G. Asthma-like symptom or “cystic fibrosis asthma”? Tuberk Toraks. 2021;69(2):167–76. https://doi.org/10.5578/tt.20219806.CrossRef

65.

Emiralioğlu N, Dogru D, Dogan Ö, Gulmez D, Akdagli S, Polat S, et al. Diverse clinical characteristics of Aspergillus growth in patients with cystic fibrosis. Turk J Pediatr. 2020;62(4).https://doi.org/10.24953/turkjped.2020.04.005.

66.

Hamad SG, Abu-Hasan M, AbdulWahab A. Use of intravenous pulse steroids to treat allergic bronchopulmonary aspergillosis in a non-compliant asthmatic adolescent. Children. 2022;9(2):252. https://doi.org/10.3390/children9020252.CrossRefPubMedPubMedCentral

67.

Hedayati MT, Tavakoli M, Maleki M, Heidari S, Mortezaee V, Gheisari M, et al. Fungal epidemiology in cystic fibrosis patients with a special focus on Scedosporium species complex. Microb Pathog. 2019;129:168–75. https://doi.org/10.1016/j.micpath.2019.02.009.CrossRefPubMed

68.

Atay Ö, Asilsoy S, Köse S, Atakul G, Al S, Boyacioğlu ÖK, et al. The importance of aeroallergen sensitivity in children with cystic fibrosis. Allergol Immunopathol (Madr). 2022;50(3):1–9. https://doi.org/10.15586/aei.v50iSP3.764.CrossRefPubMed

69.

AbdulWahab A, Salah H, Chandra P, Taj-Aldeen SJ. Persistence of Candida dubliniensis and lung function in patients with cystic fibrosis. BMC Res Notes. 2017;10(1):1–5. https://doi.org/10.1186/s13104-017-2656-z.CrossRef

70.

Irmak I, Damadoğlu E, Güven DK, Huseynova X, İnkaya AÇ, Er B, et al. Clinical implications of fungal isolation from sputum in adult patients with cystic fibrosis. Turk J Med Sci. 2021;51(3):1191–200. https://doi.org/10.3906/sag-2006-94.CrossRefPubMed

71.

Asef A, Ghafaripour HA, Jamaati H, Varahram M, Adcock IM, Mortaz E. The role of HLA-DRB1 alleles in pulmonary cystic fibrosis. Iran J Allergy Asthma Immunol. 2022:1–8.https://doi.org/10.18502/ijaai.v21i2.9226.

72.

Magee LC, Louis M, Khan V, Micalo L, Chaudary N. Managing fungal infections in cystic fibrosis patients: challenges in clinical practice. Infect Drug Resist. 2021:1141–53.https://doi.org/10.2147/IDR.S267219.

73.

Schwarz C, Bouchara J-P, Buzina W, Chrenkova V, Dmeńska H, de La Pedrosa EGG, et al. Organization of patient management and fungal epidemiology in cystic fibrosis. Mycopathologia. 2018;183:7–19. https://doi.org/10.1007/s11046-017-0205-x.CrossRefPubMed

74.

Ghazanfari M, Arastehfar A, Davoodi L, Yazdani Charati J, Moazeni M, Abastabar M, et al. Pervasive but neglected: a perspective on COVID-19-associated pulmonary mold infections among mechanically ventilated COVID-19 patients. Front Med (Lausanne). 2021;8:649675. https://doi.org/10.3389/fmed.2021.649675.CrossRefPubMed

75.

Hassanzad M, Boloursaz MR, Darougar S, Nejad ST, Mohajerani SA, Baghaie N, et al. Long term outcome of cystic fibrosis patients with multisystem evaluation. Adv Respir Med. 2016;84(6):310–5. https://doi.org/10.5603/ARM.2016.0040.CrossRefPubMed

76.

Güngör Ö, Tamay Z, Güler N, Erturan Z. Frequency of fungi in respiratory samples from Turkish cystic fibrosis patients. Mycoses. 2013;56(2):123–9. https://doi.org/10.1111/j.1439-0507.2012.02221.x.CrossRefPubMed

77.

Taj-Aldeen S, El Shafie S, Alsoub H, Eldeeb Y, De Hoog G. Isolation of Exophiala dermatitidis from endotracheal aspirate of a cancer patient. Mycoses. 2006;49(6):504–9. https://doi.org/10.1111/j.1439-0507.2006.01280.x.CrossRefPubMed

78.

Koch C, Høiby N. Diagnosis and treatment of cystic fibrosis. Respiration. 2000;67(3):239–47. https://doi.org/10.1159/000029503.CrossRefPubMed

79.

Aidoo E, Alexander S,Alshafi K, Al-Yaghchi C, Anderson AK, Balfour-Lynn I, et al. Clinical guidelines: care of children with cystic fibrosis. 2023. Available on www.rbht.nhs.uk/childrencf.

80.

Aaron SD, Vandemheen KL, Freitag A, Pedder L, Cameron W, Lavoie A, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS ONE. 2012;7(4):e36077. https://doi.org/10.1371/journal.pone.0036077.ADSCrossRefPubMedPubMedCentral

81.

Coughlan CA, Chotirmall SH, Renwick J, Hassan T, Low TB, Bergsson G, et al. The effect of Aspergillus fumigatus infection on vitamin D receptor expression in cystic fibrosis. Am J Respir Crit Care Med. 2012;186(10):999–1007. https://doi.org/10.1164/rccm.201203-0478OC.CrossRefPubMed

82.

Blomquist A, Inghammar M, Al Shakirchi M, Ericson P, Krantz C, Svedberg M, et al. Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study. BMC Pulm Med. 2022;22(1):263. https://doi.org/10.1186/s12890-022-02054-3.CrossRefPubMedPubMedCentral

83.

Soleimani Z, Teymouri P, Boloorani AD, Mesdaghinia A, Middleton N, Griffin DW. An overview of bioaerosol load and health impacts associated with dust storms: a focus on the Middle East. Atmos Environ. 2020;223:117187. https://doi.org/10.1016/j.atmosenv.2019.117187.CrossRef

84.

Nnadi NE, Carter DA. Climate change and the emergence of fungal pathogens. PLoS Pathog. 2021;17(4):e1009503. https://doi.org/10.1371/journal.ppat.1009503.CrossRefPubMedPubMedCentral

85.

Gadre A, Enbiale W, Andersen LK, Coates SJ. The effects of climate change on fungal diseases with cutaneous manifestations: a report from the International Society of Dermatology Climate Change Committee. J Clim Chang Health. 2022:100156. https://doi.org/10.1016/j.joclim.2022.100156.

86.

Chang YC, Tsai H-F, Karos M, Kwon-Chung K. THTA, a thermotolerance gene of Aspergillus fumigatus. Fungal Genet Biol. 2004;41(9):888–96. https://doi.org/10.1016/j.fgb.2004.06.004.CrossRefPubMed

87.

Kwon-Chung KJ, Sugui JA. Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen? PLoS Pathog. 2013;9(12):e1003743. https://doi.org/10.1371/journal.ppat.1003743.CrossRefPubMedPubMedCentral

88.

van Rhijn N, Bromley M. The consequences of our changing environment on life threatening and debilitating fungal diseases in humans. J Fungi (Basel). 2021;7(5):367. https://doi.org/10.3390/jof7050367.CrossRefPubMed

89.

Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses. 2009;52(3):206–22. https://doi.org/10.1111/j.1439-0507.2008.01642.x.CrossRefPubMed

90.

Erami M, Hashemi SJ, Raiesi O, Fattahi M, Getso MI, Momen-Heravi M, et al. COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia. Infection. 2023;51(1):223–30. https://doi.org/10.1007/s15010-022-01907-7.CrossRefPubMed

91.

Lang-Yona N, Shuster-Meiseles T, Mazar Y, Yarden O, Rudich Y. Impact of urban air pollution on the allergenicity of Aspergillus fumigatus conidia: outdoor exposure study supported by laboratory experiments. Sci Total Environ. 2016;541:365–71. https://doi.org/10.1016/j.scitotenv.2015.09.058.ADSCrossRefPubMed

92.

Lee P-H, Park S, Lee Y-G, Choi S-M, An M-H, Jang A-S. The impact of environmental pollutants on barrier dysfunction in respiratory disease. Allergy Asthma Immunol Res. 2021;13(6):850. https://doi.org/10.4168/aair.2021.13.6.850.CrossRefPubMedPubMedCentral

93.

Bertuzzi M, Hayes GE, Icheoku UJ, Van Rhijn N, Denning DW, Osherov N, Bignell EM. Anti-Aspergillus activities of the respiratory epithelium in health and disease. J Fungi (Basel). 2018;4(1):8. https://doi.org/10.3390/jof4010008.CrossRefPubMed

94.

Ramsay K, Stockwell R, Bell S, Kidd T. Infection in cystic fibrosis: impact of the environment and climate. Expert Rev Respir Med. 2016;10(5):505–19. https://doi.org/10.1586/17476348.2016.1162715.CrossRefPubMed

95.

Lanz B, Dietz S, Swanson T. The expansion of modern agriculture and global biodiversity decline: an integrated assessment. Ecol Econ. 2018;144:260–77. https://doi.org/10.1016/j.ecolecon.2017.07.018.CrossRef

96.

Alkhalifah DHM, Damra E, Melhem MB, Hozzein WN. Fungus under a changing climate: modeling the current and future global distribution of Fusarium oxysporum using geographical information system data. Microorganisms. 2023;11(2):468. https://doi.org/10.3390/microorganisms11020468.CrossRefPubMedPubMedCentral

97.

Garrett KA, Nita M, De Wolf E, Esker PD, Gomez-Montano L, Sparks AH. Plant pathogens as indicators of climate change. Climate change: Elsevier; 2021. 499–513.https://doi.org/10.1016/B978-0-12-821575-3.00024-4.

98.

Snelders E, Huis in’t Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75(12):4053–7. https://doi.org/10.1128/AEM.00231-09.ADSCrossRefPubMedPubMedCentral

99.

Namdar R, Karami E, Keshavarz M. Climate change and vulnerability: the case of MENA countries. Int J Geo-Inf. 2021;10(11):794. https://doi.org/10.3390/ijgi10110794.CrossRef

100.

King JA, Nichols A-L, Bentley S, Carr SB, Davies JC. An update on CFTR modulators as new therapies for cystic fibrosis. Paediatr Drugs. 2022;24(4):321–33. https://doi.org/10.1007/s40272-022-00509-y.CrossRefPubMed

101.

Salah H, Lackner M, Houbraken J, Theelen B, Lass-Flörl C, Boekhout T, et al. The emergence of rare clinical Aspergillus species in Qatar: molecular characterization and antifungal susceptibility profiles. Front Microbiol. 2019;10:1677. https://doi.org/10.3389/fmicb.2019.01677.CrossRefPubMedPubMedCentral

102.

Güngör Ö, Sampaio-Maia B, Amorim A, Araujo R, Erturan Z. Determination of azole resistance and TR 34/L98H mutations in isolates of Aspergillus section Fumigati from Turkish cystic fibrosis patients. Mycopathologia. 2018;183:913–20. https://doi.org/10.1007/s11046-018-0297-y.CrossRefPubMed

103.

Karaman M, Firinci F, Karaman O, Uzuner N, Hakki Bahar I. Long-term oropharyngeal colonization by C. albicans in children with cystic fibrosis. Yeast. 2013;30(11):429–36. https://doi.org/10.1002/yea.2977.CrossRefPubMed

104.

Wahab AA, Janahi I, Marafia M, El-Shafie S. Microbiological identification in cystic fibrosis patients with CFTR I1234V mutation. J Trop Pediatr. 2004;50(4):229–33. https://doi.org/10.1093/tropej/50.4.229.CrossRefPubMed

105.

Al Arrayed SS, Abdulla F. Incidence of cystic fibrosis in Bahrain. J Bahrain Med Soc. 1996;8:157–60.

Title: Fungal Respiratory Colonization and Infections in Cystic Fibrosis Patients in the Middle East
Authors: Mohammad T. Hedayati
Mona Ghazanfari
Bahador Nikoueian Shirvan
Sabrieh Asadi Shahi Sarae
Somayeh Ghanbari
Sanaz Yaalimadad
Shima Parsay
Shakiba Hedayati
Neda Hedayati
Martin Hoenigl
Publication date: 29-01-2024
Publisher: Springer US
Keywords: Cystic Fibrosis
Cystic Fibrosis
Aspergillus Fumigatus
Published in: Current Fungal Infection Reports / Issue 1/2024
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-024-00486-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2024

Cutaneous Infections by Geotrichum spp.

Climate Change Exacerbating Fungal Disease Disparities

One Health Approach to Addressing Fungal Infection Disparities

Pathogenesis of COVID-19-Associated Mucormycosis: An Updated Evidence-Based Review

Onychomycosis in Africa: Prevalence and Spectrum of Fungal Pathogens

Non-superficial Cutaneous Manifestations by Candida Species

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials